Benzinga | Apr 29, 2021 12:25PM EDT

Needham Maintains Buy on Cara Therapeutics, Lowers Price Target to $26

Needham analyst Joseph Stringer maintains Cara Therapeutics (NASDAQ:CARA) with a Buy and lowers the price target from $35 to $26.